National Advisory Committee on Immunization (NACI). Statement on Haemophilus influenzae type B conjugate vaccines for use in infants and children.

Currently three Haemophilus influenzae type b (Hib) conjugate vaccines are licensed for use in Canada in infants 2 months of age and older: HibTITER (Lederle Laboratories), PedvaxHIB (Merck Sharp & Dohme Canada) and Act-HIB (Pasteur-Mérieux, distributed in Canada by Connaught Laboratories Ltd.). A fourth vaccine, licensed both as a single product (ProHIBIT) or in combination with diphtheria toxoid-pertussis vaccine-tetanus toxoid (DPT-Hib) (Connaught), is limited to use in children 18 months of age or older. The following recommendations incorporate those previously published by the National Advisory Committee on Immunization(1), provide information on Act-HIB (which was licensed in March 1992) and summarize recently published data on the comparative immogenic effects and interchangeability of Hib conjugate vaccines (2-6).